Application of novel nanotechnologies in asthma
Asthma, is a very prevalent chronic pulmonary disease, affecting over 230 million people worldwide, with available treatments limited to symptoms relief (1). Considering this serious world situation, Wang et al. highlighted the nanotechnology related to delivery of drugs or biological materials, reducing side toxic effects, increasing drug bioavailability, thus improving asthma treatment. However, in this editorial comment, we sumarize the challenges that need to be overcome to nanotherapy become pertinent in clinical practice.